Peter Kolchinsky’s RA Capital Has Been Very Active This Month

Since the beginning of November, Peter Kolchinsky‘s RA Capital Management has informed the U.S. Securities and Exchange Commission that it’s increased its positions in two of its holdings: Dynavax Technologies Corporation (NASDAQ:DVAX) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

The fund now owns almost 26 million shares from Dynavax Technologies, up from 6 million previously declared. This accounts for a 9.9% stake in the company. RA Capital has also acquired about 3.6 million Achillion Pharmaceuticals shares over the last month. Following the reported transactions, RA now owns almost 20.5 million shares of the pharmaceutical company, valued at approximately $ 51.6 million. Owning about 21.2% of the firm, it stands as the largest bull amongst the hedge funds that we track, followed by Daniel Gold’s Qvt Financial.

Peter Kolchinsky

RA Capital has also become Dynavax’s largest hedge fund bull, having surpassed Arthur B Cohen and Joseph Healey’s Healthcor Management Lp, which holds about 17.6 million shares, and Samuel Isaly’s Orbimed Advisors, owner of almost 9 million shares.

Both of the aforementioned investments fit perfectly into RA Capital’s equity portfolio, composed mostly of life-sciences and drug development companies (more than 90% of the total holdings). The fund looks for companies with promising technologies and/or products. This strategy has helped the fund triple its initial investment -$4 million- in its initial two years; its portfolio is now worth more than $750 million.

Dynavax Technologies, for example, provides appealing prospects going forward (especially in terms of product development). The company focuses on the treatment and prevention of allergies, infectious diseases, and chronic inflammatory diseases, usually seeking to alter immune system responses in very specific ways. Recently, it made the design of its next clinical study for its HEPLISAV drug -an investigational adult hepatitis B vaccine- public:

“It will be an 8,000 subject, Phase 3, observer-blinded, randomized, active-controlled, multicenter trial of the safety and immunogenicity of HEPLISAV compared with Engerix-B in adults 18 to 70 years of age.”

The motivations for RA Capital to invest in Achillion, a pharmaceutical firm focused on innovative treatments for infectious diseases, are not as clear.

The FDA recently refused to remove a “hold” on clinical trials of Sovaprevir, an NS3 protease inhibitor in the treatment of hepatitis C. Consequently, the stock plummeted from more than $7 a piece in September to around $2.5 each in November, opening an attractive entry point for RA Capital, which seized the opportunity to make a value play.

Disclosure: none

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!